Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. - Wikidata - awgldk - TriplyDB

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

http://www.wikidata.org/entity/Q43787521

about

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?A case of metastatic gastric neuroendocrine tumor: therapeutic considerations.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors.90Y-edotreotide for metastatic carcinoid refractory to octreotide.ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.Multimodal management of neuroendocrine liver metastases.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)A multimodal approach to the management of neuroendocrine tumour liver metastases A new era for the systemic therapy of neuroendocrine tumors.Antitumor effects of somatostatin analogs in neuroendocrine tumors.Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.Management of Appendix Cancer.The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians.Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Refractory carcinoid syndrome: a review of treatment options.Gastrointestinal neuroendocrine tumors.Care for patients with multiple endocrine neoplasia type 1: the current evidence base.Surgical treatment of gastrointestinal neuroendocrine tumors.Somatostatin analogs for the treatment of neuroendocrine tumors.A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms.ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.Systemic therapy for advanced pancreatic neuroendocrine tumors Sunitinib malate for the treatment of pancreas malignancies--where does it fit?

P2860

Q24603675-E9BDF221-DE37-4F93-9291-144FE2AF712B Q28071978-5BEA4E04-08ED-4614-8BA9-C5C1630B13DA Q28078610-80233D7A-0BAE-43A6-9F1A-4C2A6BC67EEE Q33628260-23A542BB-BD74-4701-B3B0-D52521500F40 Q33753449-E9108A28-02DB-4114-B3E8-3BE878C14596 Q33775632-F43E8192-23AA-4BE9-9C43-3B70E2ECA579 Q34101554-C653BC51-633C-4445-8E13-4E73976DAD68 Q34248466-CBA9D40F-7E37-42AC-A887-CE418AC75F0A Q34248487-26F735FD-6774-4C0A-A009-4B532C407CA7 Q34446086-70D858AE-431D-40C5-8C14-A2988F698848 Q34452319-ACE4D2AF-A4BD-4F97-8C29-A4481D96757E Q34528199-1DC092B7-16AF-48D0-ABD8-FEDD8DD03F11 Q34965132-39EE3948-EAD9-4D0D-A0D5-290A864520B4 Q35284530-19BC6697-98CF-4584-B148-B1A9999AE29F Q35371197-00182933-BDD1-43DF-A848-65855A1261E9 Q35738251-C83CCCAE-777F-4648-89D8-1716ADE6E1FF Q35760798-559636F8-3BC7-47DC-8FE7-F0D3B3E8139B Q35810562-41F58970-498B-43B2-BC21-CADBF1742B76 Q35863865-7F169232-E437-47A8-BC2C-432434C0221C Q36051476-2A191F9A-C5D6-4C1E-8340-4E47B0D0BCD2 Q36184629-7B616FFC-DB0C-4E8D-8EE6-173B69E700DD Q36304763-7368740F-104C-41AD-9B03-BB6EE6F6AEA2 Q36962070-807B02E8-3F24-4C9F-9076-81A82F4FB6F0 Q37077832-4E7894F6-4DD1-496A-9190-49AB780E1427 Q37091117-7E4A0366-1678-4A33-BA87-7413FF5CDF41 Q37125550-6CB83002-4E09-4B32-A6EB-FFBCE9A26B83 Q37255846-D72B1A85-B70E-49EF-888B-A495BE6635E7 Q37483944-CB62E5AF-2370-413A-8D95-B5A22B493694 Q37564373-07FAC422-54AE-4C13-BF1A-1E9987CE29E5 Q37632161-BC07B2E3-2A27-4029-80BF-14D93A7A839F Q37799954-0BD3D251-7EB1-43C2-B611-04F5A2889B31 Q37808142-D5893A62-4ED9-4092-AF63-82B76F128F24 Q37833560-58F50FC9-EC78-41A6-BE7A-BAB49F95C5C8 Q37849210-00EEA0E6-7343-4329-9EF1-003B9C6908EB Q37859615-49BDD02A-B421-41BB-B58A-B09DA31FAE9D Q37977330-2860BB9A-2FE8-4892-ABA3-3E8FDDAAFE7C Q37977337-A796CCD6-920E-4341-B7AB-CAC0A656EEF6 Q38035844-D0023D5E-2B9B-4492-BC26-CEBC18E61523 Q38079854-88DCB19A-FFA6-466A-80EF-4A6AD389D3B1 Q38086310-3A2AAD06-C38F-4E0F-9640-7F05C595C921

P2860

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

http://www.wikidata.org/entity/Q43787521

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Octreotide versus octreotide p ...... ic tumors: a randomized trial.

@en

Octreotide versus octreotide p ...... ic tumors: a randomized trial.

@nl

type

label

Octreotide versus octreotide p ...... ic tumors: a randomized trial.

@en

Octreotide versus octreotide p ...... ic tumors: a randomized trial.

@nl

prefLabel

Octreotide versus octreotide p ...... ic tumors: a randomized trial.

@en

Octreotide versus octreotide p ...... ic tumors: a randomized trial.

@nl

P1433

Q43787521-648A62D6-F239-465B-A212-32130E8C8A1A

P1476

Q43787521-FF2183C0-8A54-4949-8C57-0061B8CF4D8C

P2093

Q43787521-01833FDC-8CA3-4D92-BB09-BF067423B6C5

Q43787521-196B156F-21C7-4C3F-A561-B12B07073723

Q43787521-312E4378-528D-4BAA-9714-793B8C6C9D64

Q43787521-3AB1F843-B814-46F4-8939-337A07A10849

Q43787521-50818A5A-F163-49CE-85BF-05C9850F0CA8

Q43787521-7E37CC70-2902-4172-AA7A-2DF6001DB41A

Q43787521-84BBCEFA-2E96-42B5-944A-8AAA18455FC7

Q43787521-90361E05-CFC8-4294-B3C2-FD025CF4886F

Q43787521-91B30179-3F1B-4FD9-8E58-FA4E042F0BDB

Q43787521-A43D3F32-84C2-424D-9FA3-12D1259A12EA

P304

Q43787521-B8725692-649B-46D9-A271-F02719313ED8

P31

Q43787521-5D6338D5-6644-452F-B7A1-2F3499EF3707

P356

Q43787521-BF212E21-44BB-41B7-BC2E-CDED97485D7E

P407

Q43787521-3F4154EF-C867-4B58-9206-2447AF8B184F

P433

Q43787521-30F81859-D60A-4D34-A95C-B7287BE829E4

P478

Q43787521-D5F1BE3C-0988-46D1-9E36-34A8146D5F2C

P50

Q43787521-0F3DD7FD-EADB-4CBF-B2BD-447675011A99

P577

Q43787521-7C38573A-3D52-4683-9FE5-4B42F9E7B849

P698

Q43787521-DA5BC302-8DA6-4C9E-81C5-4BCCCBD2F1AF

P356

S1542-3565(05)00481-7

P1433

Clinical Gastroenterology and Hepatology

P1476

Octreotide versus octreotide p ...... ic tumors: a randomized trial.

@en

P2093

Anja Rinke

http://www.w3.org/2001/XMLSchema#string

Christian N Arnold

http://www.w3.org/2001/XMLSchema#string

Christina Schmidt

http://www.w3.org/2001/XMLSchema#string

Hans-Helge Müller

http://www.w3.org/2001/XMLSchema#string

Karin Zamzow

http://www.w3.org/2001/XMLSchema#string

Klaus-Jochen Klose

http://www.w3.org/2001/XMLSchema#string

Marianne Pavel

http://www.w3.org/2001/XMLSchema#string

Martin Schmidt-Lauber

http://www.w3.org/2001/XMLSchema#string

Matthias Wied

http://www.w3.org/2001/XMLSchema#string

Michael Koller

http://www.w3.org/2001/XMLSchema#string

P304

761-771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1542-3565(05)00481-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Carmen Schade-Brittinger

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16234004

http://www.w3.org/2001/XMLSchema#string